Conjugates obtained by reductive amination of serotype 5 pneumococcus capsular polysaccharide
CA 2512847 C · Owner: Danve, Emilie · Inventors: Moreau, Monique; Mistretta, Noelle; Danve, Emilie
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to conjugates obtained by reductive amination of serotype 5 pneumococcus capsular polysaccharide. The reductive amination conditions differ from conventional conditions in that they avoid the creation of an undesired compound which is harmful to the immunogenicity of the conjugates. In carbon NMR spectrometry the undesired compound is , characterized by a resonance signal of 13 -14 ppm. The aminated polysaccharides involved in the production of the conjugates have a carbon NMR spectrum devoid of a resonance signal of 13 -14 ppm. The reductive amination conditions according to the invention are twofold. According to a first method, the reductive amination is …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 16, 2004 and granted August 21, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 16, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 16, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.